PeptidesFDA’s September 2026 Peptide Warning-Letter Sweep: What It Means
FDA posted warning letters to several peptide sellers on September 1. The letters focus on intended use, unapproved new drugs, misbranding, and injectable risks.
Tag
#GLP-1
5 articles
Peptides
PeptidesFDA’s 503B GLP-1 Bulks Proposal: What It Would Exclude
FDA proposed not to place semaglutide, tirzepatide, or liraglutide on the 503B Bulks List. The proposal is not a final ban or drug recall.
PeptidesWHO Starts GLP-1 Implementation Work: What the 2026 Expert Group Will Do
WHO is forming an expert group to develop practical GLP-1 implementation guidance for obesity care, with equity, affordability, and health-system readiness in scope.
PeptidesOral Wegovy in Europe: What EMA’s Tablet Decision Means
EMA’s medicines committee backed an oral Wegovy formulation in May 2026, and the European product record now lists both tablets and pre-filled pens for weight management.
PeptidesFDA’s GLP-1 Import Alert: What Changed for Bulk Drug Substances
FDA revised Import Alert 66-80 on August 21, allowing detention without physical examination of certain GLP-1 bulk drug substances while maintaining a compliance-based Green List.
The community
Bodybuilders, veterans, medical professionals & IFBB pros
The articles are the reference — the forum is where it gets real. Cycles, bloodwork, training logs, source talk.